Perspective Therapeutics (CATX) Shares Outstanding (Diluted Average) (2023 - 2026)

Perspective Therapeutics' Shares Outstanding (Diluted Average) history runs 4 years deep, the most recent figure standing at $103.6 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Diluted Average) rose 43.18% year-over-year to $103.6 million; the TTM figure through Mar 2026 stood at $103.6 million (up 43.18% YoY), while the FY2025 annual figure was $73.8 million, up 14.57% from the prior year.
• Shares Outstanding (Diluted Average) came in at $103.6 million for Q1 2026 at Perspective Therapeutics, up from $73.8 million in the prior quarter.
• In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $228.6 million in Q1 2023 to a low of $26.8 million in Q4 2023.
• A 4-year average of $73.2 million and a median of $70.6 million in 2024 frame the typical range for Shares Outstanding (Diluted Average).
• On a YoY basis, Shares Outstanding (Diluted Average) climbed as much as 151.75% in 2024 and fell as far as 78.34% in 2024.
• Perspective Therapeutics' Shares Outstanding (Diluted Average) stood at $26.8 million in 2023, then surged by 140.72% to $64.4 million in 2024, then grew by 14.57% to $73.8 million in 2025, then soared by 40.36% to $103.6 million in 2026.
• According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods registered $103.6 million, $73.8 million, and $74.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison